ARHGEF19

Across TCGA pan-cancer cohorts, ARHGEF19 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ARHGEF19 data layer compared with 20 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ARHGEF19 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARHGEF19 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC and HNSC are the cancer types where ARHGEF19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.881	0.522	.004	20	view →
HNSC	DFS	Quartile	All	0.744	0.512	.032	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ARHGEF19–LSCC (DFS)

Open the LSCC breakdown →